ABSTRACT
Invasive Aspergillus infection is a major factor for poor prognosis in patients receiving lung transplantation (LT). An antifungal agent, itraconazole (ITCZ), that has antimicrobial activity against Aspergillus species, is used as a prophylactic agent against Aspergillus infection after LT. ITCZ and its metabolite, hydroxyitraconazole (OH-ITCZ), potently inhibit CYP3A and P-glycoprotein that metabolize or excrete calcineurin inhibitors (CNIs), which are the first-line immunosuppressants used after LT; thus, concomitant use of ITCZ and CNIs could induce an increase in the blood concentration of CNIs. However, no criteria for dose reduction of CNIs upon concomitant use with ITCZ in LT recipients have been defined. In this study, the effect of ITCZ and OH-ITCZ on the blood concentrations of two CNIs, tacrolimus and cyclosporine, after LT were retrospectively evaluated. A total of 39 patients who received LT were evaluated. Effects of ITCZ and OH-ITCZ on the concentration/dosage (C/D) ratio of tacrolimus and cyclosporine were analyzed using linear mixed-effects models. The plasma concentrations of OH-ITCZ were about 2.5-fold higher than those of ITCZ. Moreover, there was a significant correlation between the plasma concentrations of ITCZ and OH-ITCZ. Based on parameters obtained in the linear regression analysis, the C/D ratios of cyclosporine and tacrolimus increase by an average of 2.25- and 2.70-fold, respectively, when the total plasma concentration of ITCZ plus OH-ITCZ is 1000 ng/mL. In conclusion, the plasma levels of ITCZ and OH-ITCZ could be key factors in drawing up the criterion for dose reduction of CNIs.
Subject(s)
Itraconazole , Tacrolimus , Cyclosporine/pharmacology , Cyclosporine/therapeutic use , Humans , Itraconazole/analogs & derivatives , Itraconazole/pharmacology , Lung , Retrospective Studies , Tacrolimus/therapeutic use , Transplant RecipientsABSTRACT
PURPOSE: Itraconazole has been repurposed as an anticancer therapeutic agent for multiple malignancies. In preclinical models, itraconazole has antiangiogenic properties and inhibits Hedgehog pathway activity. We performed a window-of-opportunity trial to determine the biologic effects of itraconazole in human patients. EXPERIMENTAL DESIGN: Patients with non-small cell lung cancer (NSCLC) who had planned for surgical resection were administered with itraconazole 300 mg orally twice daily for 10-14 days. Patients underwent dynamic contrast-enhanced MRI and plasma collection for pharmacokinetic and pharmacodynamic analyses. Tissues from pretreatment biopsy, surgical resection, and skin biopsies were analyzed for itraconazole and hydroxyitraconazole concentration, and vascular and Hedgehog pathway biomarkers. RESULTS: Thirteen patients were enrolled in this study. Itraconazole was well-tolerated. Steady-state plasma concentrations of itraconazole and hydroxyitraconazole demonstrated a 6-fold difference across patients. Tumor itraconazole concentrations trended with and exceeded those of plasma. Greater itraconazole levels were significantly and meaningfully associated with reduction in tumor volume (Spearman correlation, -0.71; P = 0.05) and tumor perfusion (Ktrans; Spearman correlation, -0.71; P = 0.01), decrease in the proangiogenic cytokines IL1b (Spearman correlation, -0.73; P = 0.01) and GM-CSF (Spearman correlation, -1.00; P < 0.001), and reduction in tumor microvessel density (Spearman correlation, -0.69; P = 0.03). Itraconazole-treated tumors also demonstrated distinct metabolic profiles. Itraconazole treatment did not alter transcription of GLI1 and PTCH1 mRNA. Patient size, renal function, and hepatic function did not predict itraconazole concentrations. CONCLUSIONS: Itraconazole demonstrates concentration-dependent early antivascular, metabolic, and antitumor effects in patients with NSCLC. As the number of fixed dose cancer therapies increases, attention to interpatient pharmacokinetics and pharmacodynamics differences may be warranted.
Subject(s)
Angiogenesis Inhibitors/administration & dosage , Carcinoma, Non-Small-Cell Lung/drug therapy , Itraconazole/administration & dosage , Neovascularization, Pathologic/drug therapy , Adult , Angiogenesis Inhibitors/adverse effects , Antineoplastic Agents/administration & dosage , Antineoplastic Agents/adverse effects , Biopsy , Carcinoma, Non-Small-Cell Lung/blood , Carcinoma, Non-Small-Cell Lung/diagnostic imaging , Carcinoma, Non-Small-Cell Lung/surgery , Female , Hedgehog Proteins/genetics , Humans , Itraconazole/analogs & derivatives , Itraconazole/blood , Itraconazole/pharmacokinetics , Magnetic Resonance Imaging , Male , Middle Aged , Neovascularization, Pathologic/blood , Neovascularization, Pathologic/diagnostic imaging , Neovascularization, Pathologic/surgery , Patched-1 Receptor/genetics , Zinc Finger Protein GLI1/geneticsABSTRACT
Dysregulation of the hedgehog (Hh) signaling pathway is associated with cancer occurrence and development in various malignancies. Previous structure-activity relationships (SAR) studies have provided potent Itraconazole (ITZ) analogues as Hh pathway antagonists. To further expand on our SAR for the ITZ scaffold, we synthesized and evaluated a series of compounds focused on replacing the triazole. Our results demonstrate that the triazole region is amenable to modification to a variety of different moieties; with a single methyl group representing the most favorable substituent. In addition, nonpolar substituents were more active than polar substituents. These SAR results provide valuable insight into the continued exploration of ITZ analogues as Hh pathway antagonists.
Subject(s)
Hedgehog Proteins/metabolism , Itraconazole/analogs & derivatives , Triazoles/chemistry , Hedgehog Proteins/antagonists & inhibitors , Humans , Inhibitory Concentration 50 , Itraconazole/metabolism , Itraconazole/pharmacology , Signal Transduction/drug effects , Structure-Activity RelationshipABSTRACT
BACKGROUND: Itraconazole (ITCZ) is used to treat pulmonary aspergillosis, but findings regarding the range of effective plasma concentrations are often contradictory. This study attempted to determine effective plasma concentrations of ITCZ and its active metabolite hydroxyitraconazole (OH-ITCZ) by retrospectively analyzing their relationships to clinical efficacy. METHODS: The study included 34 patients with pulmonary aspergillosis treated using ITCZ (mean age, 70 years). Each patient was treated with 200 mg ITCZ once daily (mean duration of treatment: 384 days). Plasma concentrations of ITCZ and OH-ITCZ at trough levels from 7 to 889 days after the start of treatment were determined using high-performance liquid chromatography. Clinical efficacy was assessed through the improvement clinical symptoms. RESULTS: Fifteen patients were classified as effective group and the other 19 patients as non-effective group. Mean (±standard deviation) ITCZ trough plasma concentration was significantly higher in effective group (1254 ± 924 ng/mL) than in non-effective group (260 ± 296 ng/mL). Mean OH-ITCZ plasma concentration was significantly higher in effective group (1830 ± 1031 ng/mL) than in non-effective group (530 ± 592 ng/mL). Receiver operating characteristic curve analysis revealed the optimal cutoff for ITCZ trough plasma concentration was 517 ng/mL, and 86.7% of effective group showed concentrations exceeding this value. The optimal cutoff for total ITCZ + OH-ITCZ plasma concentration was 1025 ng/mL, and 93.3% of effective group showed a concentration exceeding this value. CONCLUSIONS: Our findings indicate that effective plasma concentration ranges for the treatment of pulmonary aspergillosis begin at an ITCZ trough plasma concentration of 500 ng/mL and a total ITCZ + OH-ITCZ plasma concentration of 1000 ng/mL.
Subject(s)
Antifungal Agents/administration & dosage , Itraconazole/administration & dosage , Itraconazole/blood , Pulmonary Aspergillosis/drug therapy , Aged , Aged, 80 and over , Antifungal Agents/blood , Antifungal Agents/pharmacology , Female , Humans , Itraconazole/analogs & derivatives , Itraconazole/pharmacology , Male , Middle Aged , ROC Curve , Retrospective Studies , Treatment OutcomeABSTRACT
Itraconazole has been found to possess potent antiangiogenic activity, exhibiting promising antitumor activity in several human clinical studies. The wider use of itraconazole in the treatment of cancer, however, has been limited by its potent inhibition of the drug metabolizing enzyme cytochrome P450 3A4 (CYP3A4). In an effort to eliminate the CYP3A4 inhibition while retaining its antiangiogenic activity, we designed and synthesized a series of derivatives in which the 1,2,4-triazole ring is replaced with various azoles and nonazoles. Among these analogues, 15n with tetrazole in place of 1,2,4-triazole exhibited optimal inhibition of human umbilical vein endothelial cell proliferation with an IC50 of 73 nM without a significant effect on CYP3A4 (EC50 > 20 µM). Similar to itraconazole, 15n induced Niemann-Pick C phenotype (NPC phenotype) and blocked AMPK/mechanistic target of rapamycin signaling. These results suggest that 15n is a promising angiogenesis inhibitor that can be used in combination with most other known anticancer drugs.
Subject(s)
Angiogenesis Inhibitors/chemistry , Angiogenesis Inhibitors/pharmacology , Cytochrome P-450 CYP3A Inhibitors/pharmacology , Itraconazole/analogs & derivatives , Cell Proliferation/drug effects , Cytochrome P-450 CYP3A Inhibitors/chemistry , Drug Evaluation, Preclinical/methods , Human Umbilical Vein Endothelial Cells , Humans , Structure-Activity Relationship , TOR Serine-Threonine Kinases/antagonists & inhibitors , Tetrazoles/chemistryABSTRACT
In fungal cells, the endoplasmic reticulum (ER) harbors several of the enzymes involved in the biosynthesis of ergosterol, an essential membrane component, making this organelle the site of action of antifungal azole drugs, used as a first-line treatment for fungal infections. This highlights the need for specific fluorescent labeling of this organelle in cells of pathogenic fungi. Here we report on the development and evaluation of a collection of fluorescent ER trackers in a panel of Candida, considered the most frequently encountered pathogen in fungal infections. These trackers enabled imaging of the ER in live fungal cells. Organelle specificity was associated with the expression of the target enzyme of antifungal azoles that resides in the ER; specific ER labeling was not observed in mutant cells lacking this enzyme. Labeling of live Candida cells with a combination of a mitotracker and one of the novel fungal ER trackers revealed sites of contact between the ER and mitochondria. These fungal ER trackers therefore offer unique molecular tools for the study of the ER and its interactions with other organelles in live cells of pathogenic fungi.
Subject(s)
Endoplasmic Reticulum/metabolism , Fluconazole/analogs & derivatives , Fluorescent Dyes/chemistry , Itraconazole/analogs & derivatives , Antifungal Agents/chemical synthesis , Antifungal Agents/chemistry , Candida albicans/enzymology , Candida albicans/genetics , Candida albicans/metabolism , Candida glabrata/metabolism , Fluconazole/chemical synthesis , Fluorescent Dyes/chemical synthesis , Fungal Proteins/genetics , Itraconazole/chemical synthesis , Microscopy, Fluorescence/methods , Oxidoreductases/genetics , Sterol 14-Demethylase/geneticsABSTRACT
BACKGROUND: The aim of the study was to evaluate the bioequivalence of two itraconazole 100 mg capsule formulations. RESEARCH DESIGN AND METHODS: The single-center, open-label, randomized, three-period, three-sequence, reference-replicated, cross-over study included 38 healthy subjects under fed conditions. In each study period (separated by a 14-day washout), a single oral dose of the test (T) or reference (R) product was administered. Blood samples were collected at pre-dose and up to 72.0 h after administration. The calculated pharmacokinetic parameters, based on the plasma concentrations of itraconazole and hydroxy itraconazole, were AUC0-72h, AUC0-â, Cmax, Tmax, T1/2 and Kel. RESULTS: The 90% CI for the test/reference geometric means ratio for the parent compound, itraconazole, was in the range from 85.29% to 116.07% for AUC0-72h. Since the coefficient of variation (CV) for the reference product was 44.95% for Cmax, the 90% CI for this parameter for itraconazole was 93.49-133.78%, which was within the proposed limits of the EMA for bioequivalence of 72.15-138.59%. During the study, 4 subjects encountered a total of 14 mild adverse events. CONCLUSIONS: The use of the reference-scaling approach with 3-period design (TRR, RTR, and RRT) was an efficient way to demonstrate that two commercially available oral itraconazole formulations met the predetermined bioequivalence criteria.
Subject(s)
Antifungal Agents/administration & dosage , Itraconazole/analogs & derivatives , Itraconazole/administration & dosage , Administration, Oral , Adult , Antifungal Agents/pharmacokinetics , Area Under Curve , Capsules , Cross-Over Studies , Female , Half-Life , Humans , Itraconazole/pharmacokinetics , Male , Middle Aged , Therapeutic Equivalency , Young AdultABSTRACT
INTRODUCTION: Invasive fungal infections are an increasing cause of mortality and morbidity in high risk patient populations such as those on immunosuppressive therapy. Triazole antifungals are recommended for the prevention and treatment of such infections. The aim of this study was to develop and validate a simple, sensitive and robust LCMS/MS method for the simultaneous analysis in human plasma of three frequently used antifungal drugs: voriconazole, posaconazole, and itraconazole. METHODS: Precipitation reagent, containing deuterated internal standards, is added to 50µL of plasma. The vials are vortexed before centrifugation. The organic supernatant is transferred to a polypropylene vial and 1µL is injected into the Waters Acquity® Ultra Performance Liquid Chromatography system coupled with a Waters Acquity® TQ Detector system. Chromatographic separation is achieved on a BEH C18 column using gradient elution with mobile phases consisting of 2mM ammonium acetate with 0.1% formic acid in water and methanol. Run time is <5min between injections. RESULTS: The evaluation of the LCMS/MS triazole method showed good precision (intra-assay CVs<6.7%, inter-assay CVs<8.3%). The lower limit of quantitation for all antifungal triazoles tested was 0.10mg/L. Passing Bablok comparisons of voriconazole (n=50) and posaconazole (n=50) showed good correlation with the current HPLC method (Voriconazole LCMS=0.94(HPLC)+0.03, r2=0.99; Posaconazole LCMS=1.18(HPLC)-0.04, r2=0.95). Passing Bablok comparisons of itraconazole and hydroxy-itraconazole (n=18) showed good agreement with an external referral laboratory's antifungal LCMS/MS method (Itraconazole LCMS=1.00(referral lab)+0.01, r2=0.99; Hydroxy-Itraconazole LCMS=1.05(referral lab)+0.04, r2=0.99). External quality assurance samples for posaconazole and voriconazole (n=12, UK NEQAS Antifungal Pilot Panel) were assayed 'blind' and results were in good agreement with consensus mean values (both r2=0.99). CONCLUSION: The rapid pre-analytical sample preparation procedure, short chromatographic time, limit of quantitation and linear range make this LCMS/MS method suitable for determination of plasma voriconazole, posaconazole, itraconazole and hydroxy-itraconazole levels in a high throughput laboratory.
Subject(s)
Itraconazole/analogs & derivatives , Itraconazole/pharmacokinetics , Mass Spectrometry/methods , Triazoles/pharmacokinetics , Voriconazole/pharmacokinetics , Chromatography, Liquid/methods , Humans , Itraconazole/analysis , Triazoles/analysis , Voriconazole/analysisABSTRACT
OBJECTIVES: Protein-free (unbound) drug concentrations have been reported to be better biomarker of pharmacodynamics compared with total drug concentrations. In this study, we developed and validated an assay for the quantification of total and free itraconazole and hydroxyitraconazole, a main metabolite with antifungal activity, in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry (UPLC-MS/MS). DESIGN & METHODS: Plasma sample was ultra-filtrated for the measurement of free itraconazole and hydroxyitraconazole concentrations. The samples were prepared by solid phase extraction, and then subject to UPLC-MS/MS quantification. RESULTS: The assay fulfilled the requirements of the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) guidelines for assay validation, with a lower limit of quantification of 10ng/mL for total itraconazole and hydroxyitraconazole, and 0.1 and 0.5ng/mL for free itraconazole and hydroxyitraconazole, respectively. Recovery rates of total itraconazole and hydroxyitraconazole from whole plasma ranged from 53.3% to 64.0%, and recovery rates of free itraconazole and hydroxyitraconazole from ultrafiltrated plasma ranged from 81.6% to 98.7%. Matrix effect varied between 79.1% and 109.4% for total itraconazole and hydroxyitraconazole, and between 81.3% and 99.7% for free itraconazole and hydroxyitraconazole. The assay was successfully applied to therapeutic drug monitoring of itraconazole in three patients with chronic progressive pulmonary aspergillosis or invasive pulmonary aspergillosis. Plasma free hydroxyitraconazole concentrations were 8.1-, 23.3-, and 51.1-fold higher than plasma free itraconazole concentrations in the three patients. CONCLUSIONS: A method for sensitive and selective quantification of plasma total and free itraconazole and hydroxyitraconazole concentrations was developed using UPLC-MS/MS. Free hydroxyitraconazole concentration may be most important in therapeutic drug monitoring of itraconazole.
Subject(s)
Itraconazole/analogs & derivatives , Itraconazole/pharmacokinetics , Mass Spectrometry/methods , Pulmonary Aspergillosis/blood , Pulmonary Aspergillosis/drug therapy , Chromatography, High Pressure Liquid/methods , Humans , Itraconazole/administration & dosageABSTRACT
Fibrosis, a disease in which excessive amounts of connective tissue accumulate in response to physical damage and/or inflammatory insult, affects nearly every tissue in the body and can progress to a state of organ malfunction and death. A hallmark of fibrotic disease is the excessive accumulation of extracellular matrix-secreting activated myofibroblasts (MFBs) in place of functional parenchymal cells. As such, the identification of agents that selectively inhibit the transdifferentiation process leading to the formation of MFBs represents an attractive approach for the treatment of diverse fibrosis-related diseases. Herein we report the development of a high throughput image-based screen using primary hepatic stellate cells that identified the antifungal drug itraconazole (ITA) as an inhibitor of MFB cell fate in resident fibroblasts derived from multiple murine and human tissues (i.e., lung, liver, heart, and skin). Chemical optimization of ITA led to a molecule (CBR-096-4) devoid of antifungal and human cytochrome P450 inhibitory activity with excellent pharmacokinetics, safety, and efficacy in rodent models of lung, liver, and skin fibrosis. These findings may serve to provide a strategy for the safe and effective treatment of a broad range of fibrosis-related diseases.
Subject(s)
Cell Transdifferentiation/drug effects , Hepatic Stellate Cells/metabolism , Itraconazole , Liver Cirrhosis , Myofibroblasts/metabolism , Pulmonary Fibrosis , Skin Diseases , Animals , Fibrosis , Hepatic Stellate Cells/pathology , Humans , Itraconazole/analogs & derivatives , Itraconazole/pharmacology , Liver Cirrhosis/drug therapy , Liver Cirrhosis/metabolism , Liver Cirrhosis/pathology , Mice , Myofibroblasts/pathology , Pulmonary Fibrosis/drug therapy , Pulmonary Fibrosis/metabolism , Pulmonary Fibrosis/pathology , Rats , Skin Diseases/drug therapy , Skin Diseases/metabolism , Skin Diseases/pathologyABSTRACT
BACKGROUND: Triazole antifungals are essential to the treatment and prophylaxis of fungal infections. Significant pharmacokinetic variability combined with a clinical need for faster turnaround times has increased demand for in-house therapeutic drug monitoring of these drugs, which is best performed using mass spectrometry-based platforms. However, technical and logistical obstacles to implementing these platforms in hospital laboratories have limited their widespread utilization. Here, we present the development and validation of a fast and simple ultra-performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) method to measure fluconazole, voriconazole, posaconazole, itraconazole, and hydroxyitraconazole in human serum suitable for incorporation into a hospital clinical laboratory. METHODS: Serum samples (20 µL) were prepared using protein precipitation in the presence of deuterated internal standards. Chromatographic separation was accomplished using reversed phase UPLC and analysis was performed using positive-mode electrospray ionization and collision-induced dissociation MS. RESULTS: Total analytical run time was 3 min. All analytes demonstrated linearity (r2>0.998) from 0.1 to 10 µg/mL (1-100 µg/mL for fluconazole), acceptable accuracy and precision (%DEV<15% and %CV<15% at all levels tested), suitable stability under relevant storage conditions, and correlated well with reference laboratory results. CONCLUSIONS: A simple and rapid UPLC-MS/MS method for monitoring multiple triazole antifungals was developed with a focus on the needs of hospital laboratories. The assay is suitable for clinical utilization and management of patients on these medications.
Subject(s)
Antifungal Agents/blood , Blood Chemical Analysis/methods , Chromatography, High Pressure Liquid/methods , Tandem Mass Spectrometry/methods , Fluconazole/blood , Humans , Itraconazole/analogs & derivatives , Itraconazole/blood , Limit of Detection , Reproducibility of Results , Time Factors , Triazoles/blood , Voriconazole/bloodABSTRACT
Inhibition of ABC transporters is a common mechanism underlying drug-drug interactions (DDIs). We determined the inhibitory potential of antifungal drugs currently used for invasive fungal infections on ABC transporters P-glycoprotein (P-gp), MRP1 to MRP5, BCRP, and BSEP in vitro Membrane vesicles isolated from transporter-overexpressing HEK 293 cells were used to investigate the inhibitory potential of antifungal drugs (250 µM) on transport of model substrates. Concentration-inhibition curves were determined if transport inhibition was >60%. Fifty percent inhibitory concentrations (IC50s) for P-gp and BCRP were both 2 µM for itraconazole, 5 and 12 µM for hydroxyitraconazole, 3 and 6 µM for posaconazole, and 3 and 11 µM for isavuconazole, respectively. BSEP was strongly inhibited by itraconazole and hydroxyitraconazole (3 and 17 µM, respectively). Fluconazole and voriconazole did not inhibit any transport for >60%. Micafungin uniquely inhibited all transporters, with strong inhibition of MRP4 (4 µM). Anidulafungin and caspofungin showed strong inhibition of BCRP (7 and 6 µM, respectively). Amphotericin B only weakly inhibited BCRP-mediated transport (127 µM). Despite their wide range of DDIs, azole antifungals exhibit selective inhibition on efflux transporters. Although echinocandins display low potential for clinically relevant DDIs, they demonstrate potent in vitro inhibitory activity. This suggests that inhibition of ABC transporters plays a crucial role in the inexplicable (non-cytochrome P450-mediated) DDIs with antifungal drugs.
Subject(s)
ATP Binding Cassette Transporter, Subfamily B/metabolism , ATP Binding Cassette Transporter, Subfamily G, Member 2/metabolism , ATP-Binding Cassette Transporters/metabolism , Antifungal Agents/pharmacology , Multidrug Resistance-Associated Proteins/metabolism , Neoplasm Proteins/metabolism , ATP Binding Cassette Transporter, Subfamily B, Member 11 , Amphotericin B/pharmacology , Biological Transport/drug effects , Echinocandins/pharmacology , Fluconazole/pharmacology , HEK293 Cells , Humans , Itraconazole/analogs & derivatives , Itraconazole/pharmacology , Lipopeptides/pharmacology , Micafungin , Triazoles/pharmacology , Voriconazole/pharmacologyABSTRACT
BACKGROUND: In the present age of polypharmacy, limited sampling strategy becomes important to verify if drug levels are within the prescribed threshold limits from efficacy and safety considerations. The need to establish reliable single time concentration dependent models to predict exposure becomes important from cost and time perspectives. METHODS: A simple unweighted linear regression model was developed to describe the relationship between Cmax versus AUC for fexofenadine, losartan, EXP3174, itraconazole and hydroxyitraconazole. The fold difference, defined as the quotient of the observed and predicted AUC values, were evaluated along with statistical comparison of the predicted versus observed values. RESULTS: The correlation between Cmax versus AUC was well established for all the five drugs with a correlation coefficient (r) ranging from 0.9130 to 0.9997. Majority of the predicted values for all the five drugs (77%) were contained within a narrow boundary of 0.75- to 1.5-fold difference. The r values for observed versus predicted AUC were 0.9653 (n = 145), 0.8342 (n = 76), 0.9524 (n = 88), 0.9339 (n = 89) and 0.9452 (n = 66) for fexofenadine, losartan, EXP3174, itraconazole and hydroxyitraconazole, respectively. CONCLUSIONS: Cmax versus AUC relationships were established for all drugs and were amenable for limited sampling strategy for AUC prediction. However, fexofenadine, EXP3174 and hydroxyitraconazole may be most relevant for AUC prediction by a single time concentration as judged by the various criteria applied in this study.
Subject(s)
ATP Binding Cassette Transporter, Subfamily B, Member 1/pharmacokinetics , Cytochrome P-450 CYP2C9/metabolism , Cytochrome P-450 CYP3A/metabolism , Itraconazole/pharmacokinetics , Losartan/pharmacokinetics , Terfenadine/analogs & derivatives , ATP Binding Cassette Transporter, Subfamily B, Member 1/metabolism , Area Under Curve , Cross-Over Studies , Drug Interactions , Humans , Itraconazole/analogs & derivatives , Itraconazole/metabolism , Losartan/metabolism , Polypharmacy , Terfenadine/metabolism , Terfenadine/pharmacokineticsABSTRACT
Itraconazole is an orally active antifungal agent that has complex and highly variable absorption kinetics that is highly affected by food. This study aimed to develop a population pharmacokinetic model for itraconazole and the active metabolite hydroxyitraconazole, in particular, quantifying the effects of food and formulation on oral absorption. Plasma pharmacokinetic data were collected from seven phase I crossover trials comparing the SUBA-itraconazole and Sporanox formulations of itraconazole. First, a model of single-dose itraconazole data was developed, which was then extended to the multidose data. Covariate effects on itraconazole were then examined before extending the model to describe hydroxyitraconazole. The final itraconazole model was a 2-compartment model with oral absorption described by 4-transit compartments. Multidose kinetics was described by total effective daily dose- and time-dependent changes in clearance and bioavailability. Hydroxyitraconazole was best described by a 1-compartment model with mixed first-order and Michaelis-Menten elimination for the single-dose data and a time-dependent clearance for the multidose data. The relative bioavailability of SUBA-itraconazole compared to that of Sporanox was 173% and was 21% less variable between subjects. Food resulted in a 27% reduction in bioavailability and 58% reduction in the transit absorption rate constant compared to that with the fasted state, irrespective of the formulation. This analysis presents the most extensive population pharmacokinetic model of itraconazole and hydroxyitraconazole in the literature performed in healthy subjects. The presented model can be used for simulating food effects on itraconazole exposure and for performing prestudy power analysis and sample size estimation, which are important aspects of clinical trial design of bioequivalence studies.
Subject(s)
Capsules/chemistry , Itraconazole/analogs & derivatives , Itraconazole/chemistry , Itraconazole/pharmacokinetics , Administration, Oral , Adolescent , Adult , Cross-Over Studies , Female , Healthy Volunteers , Humans , Itraconazole/administration & dosage , Male , Middle Aged , Models, Theoretical , Young AdultABSTRACT
To identify the role of therapeutic drug monitoring of itraconazole (ITZ) in the setting of empirical antifungal therapy with intravenous (IV) ITZ, we performed a multicenter, prospective study in patients with hematological malignancies who had received antifungal prophylaxis with ITZ oral solution (OS). We evaluated the plasma levels of ITZ and hydroxy (OH) ITZ both before initiation of IV ITZ and on days 5-7 of IV ITZ. A total of 181 patients showed an overall success rate of 68.0 %. Prolonged baseline neutropenia and accompanying cardiovascular comorbidity were significantly associated with poor outcomes of the empirical antifungal therapy (P = 0.005 and P = 0.001, respectively). A significantly higher trough plasma level of OH ITZ per body weight was found in the patients who achieved success with empirical antifungal therapy (P = 0.036). There were no significant correlations between plasma concentrations of ITZ/OH ITZ (baseline or trough levels) and toxicities. Seven patients had a discontinuation of ITZ therapy due to toxicity. This study demonstrated that IV ITZ as empirical antifungal therapy was effective and therapeutic drug monitoring was helpful to estimate the outcome of empirical antifungal therapy in patients receiving antifungal prophylaxis with ITZ OS. To predict the outcome of empirical antifungal therapy with IV ITZ, we should evaluate baseline clinical characteristics and also perform the therapeutic drug monitoring of both ITZ and OH ITZ.
Subject(s)
Antifungal Agents/therapeutic use , Itraconazole/therapeutic use , Mycoses/drug therapy , Administration, Oral , Adult , Aged , Aged, 80 and over , Antifungal Agents/administration & dosage , Antifungal Agents/adverse effects , Antifungal Agents/blood , Chemotherapy-Induced Febrile Neutropenia/complications , Drug Monitoring , Female , Hematologic Neoplasms/complications , Humans , Itraconazole/administration & dosage , Itraconazole/adverse effects , Itraconazole/analogs & derivatives , Itraconazole/blood , Male , Middle Aged , Mycoses/etiology , Mycoses/prevention & control , Prospective Studies , Treatment Outcome , Young AdultABSTRACT
A chromatographic method (high-performance liquid chromatography/photodiode array detection) for the simultaneous determination of itraconazole and its mayor metabolite, hydroxy itraconazole, was developed. The validation data demonstrated acceptable values for linearity (dynamic range between 0.25-16 µg/mL for hydroxy itraconazole, 0.125-4 µg/mL for itraconazole), precision (Coefficient of Variation, 2.23-4.28% and 1.61-9.52% respectively), accuracy (Relative Error, -2.89 to -17.26% and -3.11 to 14.44%), selectivity, sensitivity (Lower limit of Quantification, 0.125 and 0.25 µg/mL), and recovery (97.30-105.82%) for both compounds. Its clinical suitability was also investigated in 104 trough human serum samples. The assay resulted to be rapid, sensitive, and simple for simultaneously quantification of these azole compounds in serum samples and should make a positive contribution to optimize therapies on an individual basis.
Subject(s)
Antifungal Agents/blood , Itraconazole/analogs & derivatives , Adult , Antifungal Agents/isolation & purification , Blood Chemical Analysis/standards , Child , Chromatography, High Pressure Liquid/standards , Drug Stability , Humans , Itraconazole/blood , Itraconazole/isolation & purification , Limit of Detection , Quality Control , Reference StandardsABSTRACT
A rapid and simple high-performance liquid chromatography (HPLC) assay was developed for the simultaneous determination of three triazole antifungals (voriconazole, posaconazole, and itraconazole and the metabolite of itraconazole, hydroxyitraconazole) in human plasma. Sample preparation involved a simple one-step protein precipitation with 1.0 M perchloric acid and methanol. After centrifugation, the supernatant was injected directly into the HPLC system. Voriconazole, posaconazole, itraconazole, its metabolite hydroxyitraconazole, and the internal standard naproxen were resolved on a C(6)-phenyl column using gradient elution of 0.01 M phosphate buffer, pH 3.5, and acetonitrile and detected with UV detection at 262 nm. Standard curves were linear over the concentration range of 0.05 to 10 mg/liter (r(2) > 0.99). Bias was <8.0% from 0.05 to 10 mg/liter, intra- and interday coefficients of variation (imprecision) were <10%, and the limit of quantification was 0.05 mg/liter.
Subject(s)
Antifungal Agents/blood , Chromatography, High Pressure Liquid/methods , Itraconazole/analogs & derivatives , Itraconazole/blood , Pyrimidines/blood , Triazoles/blood , Calibration , Humans , Limit of Detection , Naproxen/blood , Observer Variation , Reference Standards , Reproducibility of Results , VoriconazoleABSTRACT
BACKGROUND: The pharmacokinetic variability of hydroxy-itraconazole (OH-ITZ), an active metabolite of itraconazole (ITZ), is not fully known. METHODS: Oral solution of ITZ was administered in 46 immunocompromised patients as a single 200 mg dose for at least 12 days. The plasma concentrations of ITZ, active OH-ITZ, and keto-itraconazole (keto-ITZ), an inactive metabolite, 12 h after administration were determined by LC-UV or LC-MS/MS. RESULTS: The mean±SD of plasma concentrations of ITZ, OH-ITZ, and keto-ITZ were 833±468, 798±454, and 3.94±2.68 µg/l, respectively. A greater correlation coefficient was observed between plasma concentrations of ITZ and OH-ITZ (r=0.90, P<0.01) than between OH-ITZ and keto-ITZ (r=0.44, P<0.01). Plasma concentration of OH-ITZ was inversely correlated with concentration ratio of keto-ITZ to OH-ITZ (r=-0.52, P<0.01). Plasma concentrations of ITZ and OH-ITZ were correlated with serum concentration of albumin (r=0.36, P=0.01 and r=0.37, P=0.01) and estimated glomerular filtration rate (r=-0.27, P=0.08 and r=-0.35, P=0.02). CONCLUSIONS: The pharmacokinetic variability of OH-ITZ was associated with saturated metabolism to keto-ITZ, serum concentration of albumin, and renal function in immunocompromised patients. The plasma concentration of OH-ITZ was strongly correlated with that of ITZ. Prevention of fungal infections can be improved by determining the plasma concentration of ITZ or OH-ITZ.
Subject(s)
Antifungal Agents/pharmacokinetics , Hematologic Neoplasms/immunology , Immunocompromised Host , Immunoproliferative Disorders/immunology , Itraconazole/pharmacokinetics , Mycoses/prevention & control , Administration, Oral , Aged , Antifungal Agents/blood , Chromatography, Liquid , Drug Administration Schedule , Female , Glomerular Filtration Rate , Hematologic Neoplasms/blood , Hematologic Neoplasms/drug therapy , Hematologic Neoplasms/microbiology , Humans , Immunoproliferative Disorders/blood , Immunoproliferative Disorders/drug therapy , Immunoproliferative Disorders/microbiology , Itraconazole/analogs & derivatives , Itraconazole/blood , Male , Middle Aged , Serum Albumin/analysis , Solutions , Tandem Mass SpectrometryABSTRACT
BACKGROUND: Voriconazole and itraconazole are two broad-spectrum antifungal triazole derivates administered for the prevention and in the treatment of invasive fungal infections. Their broad inter- and intra-individual pharmacokinetic variability and the high probability of drug-drug interactions justify therapeutic drug monitoring. METHODS: After liquid-liquid extraction with tert-butyl methyl ether, chromatographic separation was achieved on a Zorbax Eclipse XDB-C18 column using gradient elution with 10 mM ammonium formate and acetonitrile. Detection was performed by a tandem mass spectrometer coupled to LC via an atmospheric pressure chemical ionization (APCI) and quantification was performed using selected reaction monitoring (SRM) transitions RESULTS: Total run time was 4.5 min. The method was validated for concentrations ranging from 0.05 to 10 µg/mL for voriconazole and from 0.025 to 5 µg/mL for itraconazole and hydroxyitraconazole, respectively. The intra- and inter-day correlation coefficients of variation were <7.7%-<9.2%, respectively. The accuracy ranged from 92.6% to 109%. CONCLUSIONS: A rapid and simple liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry (LC-APCI-MS/MS) method has been developed and validated to measure voriconazole itraconazole and hydroxyitraconazole in human plasma. This method is successfully applied to samples from patients receiving antifungal treatment.
Subject(s)
Antifungal Agents/blood , Antineoplastic Agents/blood , Chromatography, Liquid/methods , Itraconazole/analogs & derivatives , Itraconazole/blood , Pyrimidines/blood , Tandem Mass Spectrometry/methods , Triazoles/blood , Drug Monitoring , Humans , Liquid-Liquid Extraction/methods , VoriconazoleABSTRACT
PURPOSE: Zafirlukast is a substrate of cytochrome P450 2C9 (CYP2C9) and cytochrome P450 3A4 (CYP3A4) in vitro, but the role of these enzymes in its metabolism in vivo is unknown. To investigate the contribution of CYP2C9 and CYP3A4 to zafirlukast metabolism, we studied the effects of fluconazole and itraconazole on its pharmacokinetics (PK). METHODS: In a randomized crossover study, 12 healthy volunteers ingested fluconazole 200 mg (first dose 400 mg) once daily, itraconazole 100 mg (first dose 200 mg) twice daily, or placebo twice daily for 5 days, and on day 3, 20 mg zafirlukast. Plasma concentrations of zafirlukast and the antimycotics were measured up to 72 h. RESULTS: Fluconazole increased the total area under the plasma concentration-time curve (AUC) of zafirlukast 1.6-fold [95% confidence interval (CI) 1.3-2.0-fold, P < 0.001), and its peak plasma concentration 1.5-fold (95% CI 1.2-2.0-fold, P < 0.05). Fluconazole did not affect the time of peak plasma concentration or elimination half-life of zafirlukast. None of the zafirlukast PK variables differed significantly from the control in the itraconazole phase; e.g., the ratio to control of the total AUC of zafirlukast was 1.0 (95% CI 0.82-1.2) during the itraconazole phase. CONCLUSIONS: Fluconazole, but not itraconazole, increases zafirlukast plasma concentrations, strongly suggesting that CYP2C9 but not CYP3A4 participates in zafirlukast metabolism in humans.